Search Results - "Aragon, B."

CubeSats in Hydrology: Ultrahigh‐Resolution Insights Into Vegetation Dynamics and Terrestrial Evaporation by McCabe, M. F., Aragon, B., Houborg, R., Mascaro, J.

“…Abstract Satellite‐based remote sensing has generally necessitated a trade‐off between spatial resolution and temporal frequency, affecting the capacity to…”
Get full text

American Cancer Society prostate cancer survivorship care guidelines by Skolarus, Ted A., Wolf, Andrew M.D., Erb, Nicole L., Brooks, Durado D., Rivers, Brian M., Underwood, Willie, Salner, Andrew L., Zelefsky, Michael J., Aragon‐Ching, Jeanny B., Slovin, Susan F., Wittmann, Daniela A., Hoyt, Michael A., Sinibaldi, Victoria J., Chodak, Gerald, Pratt‐Chapman, Mandi L., Cowens‐Alvarado, Rebecca L.

“…Answer questions and earn CME/CNE Prostate cancer survivors approach 2.8 million in number and represent 1 in 5 of all cancer survivors in the United States…”
Get full text

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment by Aragon-Ching, Jeanny

Get full text

Role of chemotherapy in prostate cancer by Nader, Rita, El Amm, Joelle, Aragon-Ching, Jeanny

“…Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found…”
Get full text

Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib by Aragon‐Ching, Jeanny B., Madan, Ravi A.

“…Quality‐of‐life analyses such as this one for the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma…”
Get full text

Vitamin D in prostate cancer by Trump, Donald, Aragon-Ching, Jeanny

“…Signaling through the vitamin D receptor has been shown to be biologically active and important in a number of preclinical studies in prostate and other…”
Get full text

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up by Powles, Thomas, Park, Se Hoon, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Wang, Jing, Huang, Bo, Laliberte, Robert J, di Pietro, Alessandra, Grivas, Petros

“…JCO Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432) showed that avelumab first-line (1L) maintenance…”
Get full text

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer by Aragon-Ching, Jeanny B

Get full text

Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma by Aragon-Ching, Jeanny B., Uzzo, Robert

Get full text

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer by El-Amm, Joelle, Aragon-Ching, Jeanny B

“…Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an…”
Get full text

Role of immunotherapy in bladder cancer by Rhea, Logan P., Mendez-Marti, Sebastian, Kim, Davis, Aragon-Ching, Jeanny B.

“…•Checkpoint inhibitors are an established treatment for second-line therapy in metastatic urothelial cancers.•Maintenance therapy with avelumab after complete…”
Get full text

Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer by Rhea, Logan P, Aragon-Ching, Jeanny B

“…Immune checkpoint inhibitors have revolutionized the treatment of bladder urothelial cancers and have wide application in almost all disease states. Although…”
Get full text

Editorial: Radical cystectomy in bladder cancer patients by Koshkin, Vadim S, Almassi, Nima, Aragon-Ching, Jeanny B

Get full text

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer by Aragon-Ching, Jeanny

“…Darolutamide was filed as a new drug application to the United States Food and Drug Administration (US FDA) for use in the setting of nonmetastatic…”
Get full text

The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer by Gupta, Kanika, Elkon, Jacob, El-Bahesh, Ehab, Aragon-Ching, Jeanny B

“…Prostate cancer is the most common cancer among American men and the second most common cause of cancer deaths among men. Treatment of prostate cancer remains…”
Get more information

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel by GARDNER, Erin R, DAHUT, William L, SCRIPTURE, Charity D, JONES, Jacquin, ARAGON-CHING, Jeanny B, DESAI, Neil, HAWKINS, Michael J, SPARREBOOM, Alex, FIGG, William D

“…Purpose: Abraxane (ABI-007) is a 130-nm albumin-bound ( nab ) particle formulation of paclitaxel, devoid of any additional excipients. We hypothesized that…”
Get full text

INTRA-FIELD CROP YIELD VARIABILITY BY ASSIMILATING CUBESAT LAI IN THE APSIM CROP MODEL by Ziliani, M. G., Altaf, M. U., Aragon, B., Houborg, R., Franz, T. E., Lu, Y., Sheffield, J., Hoteit, I., McCabe, M. F.

“…Predicting within-field crop yield early in the season can help address crop production challenges to improve farmers’ economic return. While yield prediction…”
Get full text

Differentiation Potential of Multipotent Progenitor Cells Derived from War-Traumatized Muscle Tissue by Nesti, Leon J, Jackson, Wesley M, Shanti, Rabie M, Koehler, Steven M, Aragon, Amber B, Bailey, James R, Sracic, Michael K, Freedman, Brett A, Giuliani, Jeffrey R, Tuan, Rocky S

“…BackgroundRecent military conflicts have resulted in numerous extremity injuries requiring complex orthopaedic reconstructive procedures, which begin with a…”
Get full text

The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC) by Aslanova, Minira, Yu, Eun-Mi, Aragon-Ching, Jeanny B

“…The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last…”
Get full text

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer by Yu, Eun-Mi, Patel, Ishan, Hwang, Min Woo, Polani, Faran, Aragon-Ching, Jeanny B

“…The management of metastatic hormone-sensitive prostate cancer (mHSPC) or castration-sensitive prostate cancer (mCSPC) has become increasingly complex with the…”
Get full text